Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients

Neurology

Volumn 52, Issue 9, 1999, Pages 1896-1898

  Sciacca, F L ^a,d   Ferri, C ^a   Vandenbroeck, K ^a   Veglia, F ^a   Gobbi, G ^b   Martinelli, F ^b   Franciotta, D ^c   Zaffaroni, M ^d   Marrosu, M ^e   Martino, G ^e   Martinelli, V ^f   Comi, G ^g   Canal, N ^h   Grimaldi, L M E ^b  

^a Neuroimmunology Unit   (Belgium)

^b Experimental Neuroimmunotherapy Unit   (Belgium)

^c National Multiple Sclerosis Center   (Belgium)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^f C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^g Ospedale di Gallarate   (Italy)

^h UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ALLELE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; INFLAMMATION; INTRON; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 0033050206     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.9.1896     Document Type: Article

References (10)

1. Martin D, Near SL. Protective effect of the interleukin-1 receptor antagonist (IL-IRa) on experimental encephalomyelitis in rats. J Neuroimmunol 1995;61:241-245.
2. Nicoletti F, Patti F, Di Marco R, et al. Circulating serum levels of IL-IRa in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increase either during exacerbations or in response to IFNbeta treatment. Cytokine 1996;8:395-400.
3. Tarlow JK, Blakemore AIF, Lennard A, et al. Polymorphism in human receptor antagonist gene intron 2 is caused by variable number of 86 bp tandem repeat. Hum Genet 1993;91: 403-404.
4. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subjects variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1997;99:303-310.
5. Crusius JBA, Pena AS, vanOsten BW, et al. Interleukin 1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet 1995;346:979-980.
6. Huang WX, He B, Hillert J. An interleukin 1-receptor-antagonist gene polymorphism is not associated with multiple sclerosis. J Neuroimmunol 1996;67:143-144.
7. Epplen C, Jäckel S, Santos EJ, et al. Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann Neurol 1997;41:341-352.
8. Semana G, Yaouanq J, Alizadeh M, Clanet M, Edan G. Interleukin-1 receptor antagonist gene in multiple sclerosis. Lancet 1997;349:476. Letter.
9. Wansen K, Pastinen T, Kuokkanen S, et al. Immune system genes in multiple sclerosis: genetic association and linkage analyses on TCRβ, ICH, IFN-γ and IL-1Ra/IL-1β loci. J Neuroimmunol 1997;79:29-36.
10. De la Concha EG, Arroyo R, Crusius JB, et al. Combined effect of HLA-DRB1* 1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol 1997;8:172-178.